Skip to main content

Market Overview

Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates

Share:
  • Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms. 
  • Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates to treat various life-threatening and debilitating diseases.
  • UCLA will work to propose potential antibody drug candidates. The collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements for selected candidates.
  • Price Action: XNCR closed 0.3% higher at $48.5 on Wednesday.
 

Related Articles (XNCR)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com